The search space for protein engineering grows exponentially with complexity. A protein of just 100 amino acids has 20100 ...

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...

DNA polymerase epsilon catalytic subunit A (POLE) gene plays a crucial role in DNA repair and chromosomal replication. Mutations in the POLE gene have ...

The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Disparate as they may be, though, both halves are extremely compelling. Requiem feels like Resident Evil's developers, for ...

The search space for protein engineering grows exponentially with complexity. A protein of just 100 amino acids has 20^100 possible variants-more combinations than atoms in the observable universe.

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...

The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...

Moore and Michael have been researching a recently-discovered hybrid "mutant" seagrass, one that demonstrates low-light tolerance.

One woman shares her story of hope living with a rare and aggressive brain cancer. Jennifer's* story begins in a small town ...